Oncotarget

Research Papers:

Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention: a meta-analysis

Ming-Ming Zhang _, Ying-Ying Zheng, Ying Gao, Jing-Zhan Zhang, Fen Liu, Yi-Ning Yang, Xiao-Mei Li, Yi-Tong Ma and Xiang Xie

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:83437-83450. https://doi.org/10.18632/oncotarget.13118

Metrics: PDF 582 views  |   HTML 858 views  |   ?  


Abstract

Ming-Ming Zhang1, Ying-Ying Zheng2, Ying Gao3, Jing-Zhan Zhang2, Fen Liu2, Yi-Ning Yang2, Xiao-Mei Li2, Yi-Tong Ma2, Xiang Xie2

1Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471000, China

2Heart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China

3Department of Cadre ward, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China

Correspondence to:

Xiang Xie, email: xiangxie999@sina.com

Keywords: coronary heart disease, restenosis, heme oxygenase-1 gene, polymorphism, meta-analysis

Received: July 07, 2016     Accepted: October 19, 2016     Published: November 04, 2016

ABSTRACT

Numerous published studies have suggested that there is association between heme oxygenase-1 (HO-1) gene polymorphisms and coronary heart disease (CHD) or restenosis (RS) after percutaneous coronary intervention (PCI). This study aimed to clarify this association using a meta-analysis method. We used a systematic search for studies on the association of HO-1gene polymorphisms with CHD or RS in PubMed, Web of Science, the Cochrane Library, Wanfang Data and CNKI (China National Knowledge Infrastructure). We used Stata 12.0 software to perform the meta-analyses. Twenty-three studies, involving 12,130 patients with CHD or RS and 14,181 controls, were included. A statistically significant association between the HO-1(GT)n repeat length polymorphism and CHD was observed under allelic (odds ratio (OR) = 0.929, 95% confidence interval (CI) = 0.881-0.978, p= 0.005), recessive (OR = 0.858, 95%CI = 0.780-0.945, p= 0.002), and co-dominant (OR = 0.843, 95%CI = 0.754-0.942, p= 0.003) models. Moreover, we also found a statistically significant association between the HO-1(GT)n repeat length polymorphism and RS under allelic (OR = 0.718, 95%CI = 0.541-0.953, p= 0.022) and co-dominant (OR = 0.522, 95%CI = 0.306-0.889, p=0.017) models. We found a significant association of the HO-1T(-413)A single-nucleotide polymorphism (SNP) with CHD under allelic (OR = 0.915, 95%CI = 0.842-0.995, p= 0.038), recessive (OR = 0.869, 95%CI = 0.760-0.994, p= 0.041), and co-dominant (OR = 0.792, 95%CI = 0.663-0.946, p=0.010) models. Our study indicates that both the HO-1(GT)n repeat length polymorphism and the T(-413)A SNP are associated with decreased risk of CHD. The (GT)n repeat length polymorphism was associated with RS following PCI.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13118